Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer

Journal of Molecular Medicine

Volumn 80, Issue 9, 2002, Pages 585-594

  Wang, Qingqing ^a   Yu, Hai ^a   Zhang, Lihuang ^a   Ju, Dianwen ^b   Pan, Jianping ^a   Xia, Dajing ^a   Yao, Hangping ^a   Zhang, Weiping ^b   Wang, Jianli ^a   Cao, Xuetao ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor effect; Gene therapy; Immunotherapy; Lymphotactin; Superantigen

Indexed keywords

ADENOVIRUS VECTOR; FUSION PROTEIN C215FAB STAPHYLOCOCCAL ENTEROTOXIN A; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; LYMPHOTACTIN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C215; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN; UNCLASSIFIED DRUG; CYTOKINE; ENTEROTOXIN; ENTEROTOXIN A, STAPHYLOCOCCAL; GAMMA CHEMOKINE; LYMPHOKINE; SIALOGLYCOPROTEIN; TUMOR ANTIGEN; XCL1 PROTEIN, HUMAN; XCL1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE THERAPY; GENE TRANSFER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN INDUCTION; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; ADENOVIRUS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CELL LINE; CELL TRANSPLANTATION; EXPERIMENTAL MELANOMA; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL LINE; CELL TRANSPLANTATION; CHEMOKINES, C; COMBINED MODALITY THERAPY; CYTOKINES; ENTEROTOXINS; FEMALE; GENE TRANSFER TECHNIQUES; IMMUNOGLOBULIN FAB FRAGMENTS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOKINES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SIALOGLYCOPROTEINS; SUPERANTIGENS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0036381570     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-002-0345-3     Document Type: Article

References (50)

1. + helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigen. J Exp Med 169:457-467
2. + T cells clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 146:3235-3241
3. Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA (1991) Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immunother 10:153-164
4. White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P (1989) The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 56:27-35
5. Fischer H, Dohlsten M, Andersson U, Hedlund G, Ericsson P, Hansson J, Sjogren HO (1990) Production of TNF-alpha and TNF-beta by staphylococcal enterotoxin A activated human T cells. J Immunol 144:4663-4669
6. Dohlsten M, Sundstedt A, Bjorklund M, Hedlund G, Kalland T (1993) Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer 54:482-488
7. Dohlsten M, Bjorklund M, Sundstedt A, Hedlund G, Samson D, Kalland T (1993) Immunopharcology of the superantigen staphylococcal enterotoxin A in T cells receptor V beta 3 transgenic mice. Immunology 79:520-527
8. Dohlsten M, Abrahmsen L, Bjork P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NR, Forberg C, Lind P (1994) Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA 91:8945-8949
9. Ihle J, Holzer U, Krull F, Dohlsten M, Kalland T, Niethammer D, Dannecker GE (1995) Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines. Cancer Res 55:623-628
10. Lando PA, Dohlsten M, Ohlsson L, Kalland T (1995) Tumor-reactive superantigens suppress tumor growth in humanized SCID mice. Int J Cancer 62:466-471
11. Dohlsten M, Lando PA, Bjork P, Abrahmsen L, Ohlsson L, Lind P, Kalland T (1995) Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother 41:162-168
12. Dohlsten M, Hansson J, Ohlsson L, Litton M, Kalland T (1995) Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci USA 92:9791-9795
13. Litton MJ, Dohlsten M, Lando PA, Kalland T, Ohlsson L, Andersson J, Andersson U (1996) Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 26:1-9
14. Rosendahl A, Hansson J, Sundstedt A, Kalland T, Dohlsten M (1996) Immune response during tumor therapy with antibody-superantigen fusion proteins. Int J Cancer 68:109-113
15. Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, Shannon B, Guedez Y, Kotb M, Vitek L, Persson R, Gunnarsson PO, Kalland T, Dohlsten M, Persson B, Weiner LM (1997) Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol 15:1994-2007
16. Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M (1998) Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. J Immunol 160:5309-5313
17. Nielsen SE, Zeuthen J, Lund B, Persson B, Alenfall J, Hansen HH (2000) Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma. J Immunother 23:146-153
18. Rosendahl A, Kristensson K, Carlsson M, Skartved NJ, Riesbeck K, Sogaard M, Dohlsten M (1999) Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. Int J Cancer 81:156-163
19. Yoshida T, Imai T, Takagi S, Nishimura M, Ishikawa I, Yaoi T, Yoshie O (1996) Structure and expression of two highly related genes encoding SCM-1/human lymphotactin. FEBS Lett 95:82-88
20. Kennedy J, Kelner GS, Kleyensteuber S, Schall TJ, Weiss MC, Yssel H, Schneider PV, Cocks BG, Bacon KB, Zlotnik A (1995) Molecular cloning and functional characterization of human lymphotactin. J Immunol 155:203-209
21. Giancarlo B, Silvano S, Albert Z, Mantovani A, Allavena P (1996) Migratory response of human natural killer cells to lymphotactin. Eur J Immunol 26:3238-3241
22. Hedrick JA, Zlotnik A (1997) Lymphotactin: a new class of chemokine. Methods Enzymol 287:206-215
23. Hedrick JA, Saylor V, Figueroa D, Mizoue L, Xu Y, Menon S, Abrams J, Handel T, Zlotnik A (1997) Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J Immunol 158:1533-1540
24. Hedrick JA, Zlotnik A (1998) Lymphotactin. Clin Immunol Immunopathol 87:218-222
25. Yoshida T, Ishikawa I, Ono Y, Imai T, Suzuki R, Yoshie O (1999) An activation-responsive element in single C motif-1/lymphotactin promoter is a site of constitutive and inducible DNA-protein interactions involving nuclear factor of activated T cell. J Immunol 163:3295-3303
26. Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A, Brenner M (1996) Combined chemokines and cytokines gene transfer enhances antitumor immunity. Nat Med 2:1090-1095
27. Ju DW, Tao Q, Cheng DS, Zhang W, Zhang M, Hamada H, Cao X (2000) Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Gene Ther 7:329-338
28. Zhang W, He L, Yuan Z, Xie Z, Wang J, Hamada H, Cao X (1999) Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum Gene Ther 10:1151-1161
29. Wang Q, Yu H, Ju DW, He L, Pan JP, Xia DJ, Zhang LH, Cao X (2001) Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. Gene Ther 8:542-550
30. Bjork P, Jonsson U, Svedberg H, Larsson K, Lind P, Dillner J, Hedlund G, Dohlsten M, Kalland T (1993) Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J Biol Chem 268:24232-24241
31. Cao X, Zhang W, He L, Xie Z, Ma S, Tao Q, Yu Y, Hamada H, Wang J (1998) Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol 161:6238-6244
32. Cruikshank WW, Berman JS, Theodore AC, Bernardo J, Center DM (1987) Lymphokine activation of T4+ T lymphocytes and monocytes. J Immunol 138:3817-3823
33. Lei H, Ju DW, Yu Y, Tao Q, Chen G, Gu S, Hamada H, Cao X (2000) Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrets macrophage colony-stimulating factor and interferon-γ. Gene Ther 7:707-771
34. Blankenstein T, Qin Z (1996) Cancer Vaccine. Gene Ther 3:95-96
35. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153:421-427
36. Walden P (2000) Hybrid cell vaccination for cancer immunotherapy. Adv Exp Med Biol 465:347-354
37. Bubenik J (1999) Granulocyte-macrophage colony-stimulating factor gene-modified vaccines for immunotherapy of cancer. Folia Biol (Praha) 45:115-119
38. Pardoll DM (1999) Cancer Vaccines. Nat Med 4:525-531
39. Ben-Baruch A, Michiel DF, Oppenheim JJ (1995) Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem 270:11703-11706
40. Baggiolini M, Dewald B, Moser B (1994) Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 55:97-179
41. Sozzani S, Sallusto F, Luini W, Zhou D, Piemonti L, Allavena P, Van Damme J, Valitutti S, Lanzavecchia A, Mantovani A (1995) Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol 155:3292-3295
42. Nakashima E, Oya A, Kubota Y, Kanada N, Matsushita R, Takeda K, Ichimura F, Kuno K, Mukaida N, Hirose K, Nakanishi I, Ujiie T, Matsushima K (1996) A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm Res 13:1896-1901
43. Mule JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV, Rosenberg SA, Schall TJ (1996) RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 20:1545-1553
44. Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH, Broxmeyer HE, Cornetta K (2000) The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 164:4025-4031
45. Fushimi T, Kojima A, Moore MA, Crystal RG (2000) Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 105:1383-1393
46. Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, Gauldie J (1999) Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther 10:697-709
47. Shrayer DP, Kouttab N, Hearing VJ, Wanebo HJ (1998) Immunization of mice with melanoma cells transfected to secrete the superantigen, staphylococcal enterotoxin A. Cancer Immunol Immunother 46:7-13
48. Belfrage H, Bhiladvala P, Hedlund G, Dohlsten M, Kalland T (1994) Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity. Cancer Immunol Immunother 38:265-271
49. Lotze MT (1996) Cytokine gene therapy of cancer. Cancer 2:63-72
50. Farzaneh F, Trefzer F, Sterry W, Walden P (1998) Gene therapy of cancer. Immunol Today 19:294-296